A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
|Articles|December 1, 1996
Supplements and Featured Publications
- Pharmacoeconomic and Healthcare Outcomes Research: Managing and Treating Hypertension and Cardiovas
- Volume 2
- Issue 12 Suppl
Introduction
Advertisement
Articles in this issue
almost 30 years ago
Gatekeepers and Managed Care: Too Much of a Good Thing?almost 30 years ago
MANAGED CARE CLINICAL CORNER: Chest Painalmost 30 years ago
Selected AbstractsAdvertisement
Related to this article
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
Medicare Advantage plans have varied motivations, strategies, and aspirations for addressing health-related social needs among home health beneficiaries, highlighting a need to expand the scope of supplemental benefits.
2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.
Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.
We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
5